If you have type 2 diabetes and chronic kidney disease (CKD), you know the struggle of managing both conditions together. Diabetes is one of the leading causes of kidney disease in the UK, and watching your kidneys decline is frightening. But new trial data shows that semaglutide – the active ingredient in Ozempic and Wegovy – may offer real protection for your kidneys.
What is semaglutide and how does it help kidneys?
Semaglutide is a GLP-1 receptor agonist – a type of medicine that was originally developed to help people with type 2 diabetes manage their blood sugar. It works by helping your body produce more insulin and making your body more responsive to it. But in recent years, researchers have discovered that it also has direct protective effects on the kidneys themselves, beyond just controlling blood sugar.
The FLOW trial, one of the largest kidney-focused studies of this medicine, followed thousands of people with type 2 diabetes and chronic kidney disease over several years. The results were significant: semaglutide reduced the risk of kidney-related events – including progression to kidney failure – and also reduced the risk of death from cardiovascular (heart) causes.
You can read the full original research from PubMed here: Ozempic keeps wowing: trial data show benefits for kidney disease.
Could a diabetes drug help protect kidneys?
At MRIKPA, we’re excited about findings like this because they give people with diabetic kidney disease more options to slow the progress of their condition. If semaglutide can help you keep your kidneys working longer, that means delaying or possibly preventing dialysis. That’s life-changing. For those already on dialysis, it might mean better overall health and fewer complications. And if you’re earlier in your kidney disease journey, it could buy you valuable years.
Every advance in managing diabetic kidney disease keeps people healthier, independent, and off dialysis for longer. These kinds of evidence-based treatments represent the future of kidney care.
– Guy Hill, Chair of MRIKPA
Strong trial results, but questions remain
Here’s the honest truth: semaglutide is not a cure. It doesn’t reverse kidney damage that’s already happened. And it’s not automatically available to everyone – whether you can access it through the NHS depends on your specific circumstances and what your doctor recommends. Some people experience side effects, and it’s not suitable if you have certain health conditions.
What it does mean is that if you have type 2 diabetes and CKD, you should ask your doctor or renal team whether semaglutide might be right for you. The evidence suggests it could help slow your kidney disease progression, which could make a real difference to your quality of life and how long your kidneys keep working.
For more information about managing diabetes and kidney health, visit our diet tips for CKD patients page, or get in touch at support@mrikpa.org.uk or 07745 242 684.
Source: PubMed / FLOW Trial, 2024 – read the original article
This article is provided for general information and awareness purposes only and was believed to be accurate at the time of publishing. It is not intended as medical advice – please always consult your doctor or renal team for guidance on your individual circumstances. Images used are for illustration purposes only and may not be medically or editorially accurate. While we take every care, errors can occur. If you spot an inaccuracy, please let us know at support@mrikpa.org.uk.
